Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.
Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Clin Infect Dis. 2023 Apr 19;76(76 Suppl1):S114-S122. doi: 10.1093/cid/ciac967.
To address a paucity of data from sub-Saharan Africa, we examined the prevalence, severity, and seasonality of norovirus genogroup II (NVII) among children <5 years old in The Gambia, Kenya, and Mali following rotavirus vaccine introduction.
Population-based surveillance was conducted to capture medically-attended moderate-to-severe diarrhea (MSD) cases, defined as a child 0-59 months old passing ≥3 loose stools in a 24-hour period with ≥1 of the following: sunken eyes, poor skin turgor, dysentery, intravenous rehydration, or hospitalization within 7 days of diarrhea onset. Diarrhea-free matched controls randomly selected from a censused population were enrolled at home. Stools from cases and controls were tested for enteropathogens, including norovirus and rotavirus, by TaqMan quantitative polymerase chain reaction (PCR) and conventional reverse transcription PCR. We used multiple logistic regression to derive adjusted attributable fractions (AFe) for each pathogen causing MSD, which takes into consideration the prevalence in both cases and controls, for each site and age. A pathogen was considered etiologic if AFe was ≥0.5. In further analyses focusing on the predominant NVII strains, we compared rotavirus and NVII severity using a 20-point modified Vesikari score and examined seasonal fluctuations.
From May 2015 to July 2018, we enrolled 4840 MSD cases and 6213 controls. NVI was attributed to only 1 MSD episode. NVII was attributed to 185 (3.8%) of all MSD episodes and was the sole attributable pathogen in 139 (2.9%); peaking (36.0%) at age 6-8 months with majority (61.2%) aged 6-11 months. MSD cases whose episodes were attributed to NVII alone compared with rotavirus alone were younger (median age, 8 vs 12 months, P < .0001) and had less severe illness (median Vesikari severity score, 9 vs 11, P = .0003) but equally likely to be dehydrated. NVII occurred year-round at all study sites.
Infants aged 6-11 months bear the greatest burden of norovirus disease, with NVII predominating. An early infant vaccine schedule and rigorous adherence to guidelines recommended for management of dehydrating diarrhea may offer substantial benefit in these African settings.
为了解决撒哈拉以南非洲地区数据匮乏的问题,我们研究了诺如病毒基因 II 组(NVII)在冈比亚、肯尼亚和马里引入轮状病毒疫苗后 5 岁以下儿童中的流行率、严重程度和季节性。
进行了基于人群的监测,以捕获经医学治疗的中度至重度腹泻(MSD)病例,定义为 0-59 个月大的儿童在 24 小时内有≥3 次稀便,并有以下至少 1 种症状:眼窝凹陷、皮肤弹性差、痢疾、静脉补液或腹泻发作后 7 天内住院。从人口普查人群中随机选择的无腹泻的匹配对照在家中招募。从病例和对照中采集粪便,采用 TaqMan 定量聚合酶链反应(PCR)和常规逆转录 PCR 检测诺如病毒和轮状病毒等肠道病原体。我们使用多因素逻辑回归来计算每个病原体引起 MSD 的调整归因分数(AFE),该分数考虑了病例和对照中的流行率,针对每个地点和年龄进行计算。如果 AFE 大于等于 0.5,则认为病原体是病因。在进一步关注主要 NVII 株的分析中,我们使用 20 点改良 Vesikari 评分比较了轮状病毒和 NVII 的严重程度,并检查了季节性波动。
2015 年 5 月至 2018 年 7 月,我们纳入了 4840 例 MSD 病例和 6213 例对照。只有 1 例 MSD 发作归因于 NVI。NVII 归因于所有 MSD 发作的 185 例(3.8%),在 139 例(2.9%)中是唯一的病原体;在 6-8 月龄时达到高峰(36.0%),其中大多数(61.2%)年龄在 6-11 个月。与单独轮状病毒相比,仅由 NVII 引起的 MSD 发作的病例更年轻(中位数年龄为 8 个月 vs 12 个月,P<0.0001),病情较轻(中位数 Vesikari 严重程度评分,9 分 vs 11 分,P=0.0003),但脱水的可能性同样高。NVII 在所有研究地点全年都有发生。
6-11 月龄婴儿感染诺如病毒的负担最大,NVII 占主导地位。在这些非洲环境中,早期婴儿疫苗接种计划和严格遵守推荐的管理脱水性腹泻的指南可能会带来实质性的益处。